GNI Group Ltd.

TSE:2160 Stock Report

Market Cap: JP¥182.7b

GNI Group Valuation

Is 2160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 2160 (¥2915) is trading below our estimate of future cash flow value (¥6331.45)

Significantly Below Future Cash Flow Value: 2160 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2160?

Key metric: As 2160 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2160. This is calculated by dividing 2160's market cap by their current revenue.
What is 2160's PS Ratio?
PS Ratio7.1x
SalesJP¥27.05b
Market CapJP¥182.74b

Price to Sales Ratio vs Peers

How does 2160's PS Ratio compare to its peers?

The above table shows the PS ratio for 2160 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.3x
4587 PeptiDream
6.7x17.47%JP¥126.7b
219A Heartseed
13.8x40.96%JP¥41.7b
7774 Japan Tissue Engineering
12.8xn/aJP¥32.4b
7777 3-D Matrix
4.1xn/aJP¥44.3b
2160 GNI Group
6.6x20.81%JP¥178.9b

Price-To-Sales vs Peers: 2160 is good value based on its Price-To-Sales Ratio (7.1x) compared to the peer average (9.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 2160's PS Ratio compare vs other companies in the JP Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
4974 Takara Bio
3.4xn/aUS$858.49m
7777 3-D Matrix
4.1xn/aUS$280.48m
2929 Pharma Foods International
0.2x3.89%US$104.49m
4584 Kidswell Bio
1.1x1.15%US$46.08m
2160 7.1xIndustry Avg. 17.2xNo. of Companies6PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2160 is good value based on its Price-To-Sales Ratio (7.1x) compared to the JP Biotechs industry average (17.2x).

Price to Sales Ratio vs Fair Ratio

What is 2160's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2160 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.1x
Fair PS Ratio3.4x

Price-To-Sales vs Fair Ratio: 2160 is expensive based on its Price-To-Sales Ratio (7.1x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2160 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥2,915.00
JP¥4,400.00
+50.94%
13.64%JP¥5,000.00JP¥3,800.00n/a2
Aug ’27JP¥2,475.00
JP¥4,400.00
+77.78%
13.64%JP¥5,000.00JP¥3,800.00n/a2
Jun ’27JP¥2,574.00
JP¥4,400.00
+70.94%
13.64%JP¥5,000.00JP¥3,800.00n/a2
May ’27JP¥3,020.00
JP¥4,400.00
+45.70%
13.64%JP¥5,000.00JP¥3,800.00n/a2
Apr ’27JP¥3,200.00
JP¥4,300.00
+34.38%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Mar ’27JP¥3,160.00
JP¥4,300.00
+36.08%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Feb ’27JP¥2,548.00
JP¥4,300.00
+68.76%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Jan ’27JP¥2,412.00
JP¥4,300.00
+78.28%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Dec ’26JP¥2,476.00
JP¥4,300.00
+73.67%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Nov ’26JP¥2,436.00
JP¥4,300.00
+76.52%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Oct ’26JP¥2,346.00
JP¥4,300.00
+83.29%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Sep ’26JP¥2,691.00
JP¥4,300.00
+59.79%
16.28%JP¥5,000.00JP¥3,600.00n/a2
Aug ’26JP¥2,792.00
JP¥4,300.00
+54.01%
16.28%JP¥5,000.00JP¥3,600.00JP¥2,475.002
Jul ’26JP¥3,300.00
JP¥4,500.00
+36.36%
11.11%JP¥5,000.00JP¥4,000.00JP¥2,791.002
May ’26JP¥2,390.00
JP¥3,850.00
+61.09%
3.90%JP¥4,000.00JP¥3,700.00JP¥3,020.002
Apr ’26JP¥2,056.00
JP¥3,850.00
+87.26%
3.90%JP¥4,000.00JP¥3,700.00JP¥3,200.002
Mar ’26JP¥3,375.00
JP¥3,850.00
+14.07%
3.90%JP¥4,000.00JP¥3,700.00JP¥3,160.002
Feb ’26JP¥3,350.00
JP¥3,850.00
+14.93%
3.90%JP¥4,000.00JP¥3,700.00JP¥2,548.002
Jan ’26JP¥3,405.00
JP¥3,850.00
+13.07%
3.90%JP¥4,000.00JP¥3,700.00JP¥2,412.002
Dec ’25JP¥3,300.00
JP¥3,850.00
+16.67%
3.90%JP¥4,000.00JP¥3,700.00JP¥2,476.002
Nov ’25JP¥3,025.00
JP¥3,850.00
+27.27%
3.90%JP¥4,000.00JP¥3,700.00JP¥2,436.002
Oct ’25JP¥3,035.00
JP¥3,850.00
+26.85%
3.90%JP¥4,000.00JP¥3,700.00JP¥2,346.002
JP¥4.4k
Fair Value
33.8% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/10 15:52
End of Day Share Price 2026/08/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GNI Group Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephen BarkerJefferies LLC
Yuriko IshidaMizuho Securities Co., Ltd.
null nullStorm Research Limited